Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 14:14:1301017.
doi: 10.3389/fendo.2023.1301017. eCollection 2023.

G protein-coupled receptors and obesity

Alessandro Pocai  1
Affiliations
Review

G protein-coupled receptors and obesity

Alessandro Pocai. Front Endocrinol (Lausanne). .

Abstract

G protein-coupled receptors (GPCRs) have emerged as important drug targets for various chronic diseases, including obesity and diabetes. Obesity is a complex chronic disease that requires long term management predisposing to type 2 diabetes, heart disease, and some cancers. The therapeutic landscape for GPCR as targets of anti-obesity medications has undergone significant changes with the approval of semaglutide, the first peptide glucagon like peptide 1 receptor agonist (GLP-1RA) achieving double digit weight loss (≥10%) and cardiovascular benefits. The enhanced weight loss, with the expected beneficial effect on obesity-related complications and reduction of major adverse cardiovascular events (MACE), has propelled the commercial opportunity for the obesity market leading to new players entering the space. Significant progress has been made on approaches targeting GPCRs such as single peptides that simultaneously activate GIP and/or GCGR in addition to GLP1, oral tablet formulation of GLP-1, small molecules nonpeptidic oral GLP1R and fixed-dose combination as well as add-on therapy for patients already treated with a GLP-1 agonist.

Keywords: GIP; GLP-1; amylin; glucagon; obesity; semaglutide; tirzepatide.

PubMed Disclaimer

Conflict of interest statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
G-protein coupled receptors (GPCRs) and peptides discussed. The anorexigenic hormones (blue) are released from various organs mostly in the gastrointestinal system and pancreas and modulate GPCRs leading to food intake suppression, reduced gastric emptying and increased energy expenditure. Inset. GPCR signaling: Balanced agonists activate both the G protein- and β-arrestin-dependent signaling pathway while biased agonists selectively activate the GPCR-dependent signaling pathway affecting cellular response through second messenger activation or the β-arrestin-dependent signaling pathway. Glucagon-like peptide-1 (GLP-1), oxyntomodulin (OXM), gastric inhibitory polypeptide (GIP), peptide YY (PYY), cannabinoid receptor 1 (CB1R), Leap-2 (Liver-expressed antimicrobial peptide 2), melanocortin 4 receptor (MC4R), amylin receptor (AmR), 5-hydroxytryptamine receptor 2C (5-HT2CR). AgRP (Agouti-Related Protein), POMC (proopiomelanocortin); NTS, nucleus tractus solitarius; ARC, Arcuate nucleus; PVN, paraventricular nucleus.
Figure 2
Figure 2
Timeline and discoveries discussed in this minireview with therapeutic relevance in obesity.
See this image and copyright information in PMC

References

    1. Sriram K, Insel PA. G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs? Mol Pharmacol (2018) 93(4):251–8. doi: 10.1124/mol.117.111062 - DOI - PMC - PubMed
    1. Ryan DH. Next generation antiobesity medications: setmelanotide, semaglutide, tirzepatide and bimagrumab: what do they mean for clinical practice? J Obes Metab Syndr (2021) 30(3):196–208. doi: 10.7570/jomes21033 - DOI - PMC - PubMed
    1. Melson E, Miras AD, Papamargaritis D. Future therapies for obesity. Clin Med (Lond) (2023) 23(4):337–46. doi: 10.7861/clinmed.2023-0144 - DOI - PMC - PubMed
    1. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med (2017) 376(3):254–66. doi: 10.1056/NEJMra1514009 - DOI - PubMed
    1. Pantalone KM, Hobbs TM, Chagin KM, Kong SX, Wells BJ, Kattan MW, et al. Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system. BMJ Open (2017) 7(11):e017583. doi: 10.1136/bmjopen-2017-017583 - DOI - PMC - PubMed